- Home
- IONS vs NJR Comparison
IONS vs NJR Comparison
Compare IONS & NJR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- NJR
- Stock Information
- Founded
- IONS 1989
- NJR 1922
- Country
- IONS United States
- NJR United States
- Employees
- IONS N/A
- NJR N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- NJR Oil/Gas Transmission
- Sector
- IONS Health Care
- NJR Utilities
- Exchange
- IONS Nasdaq
- NJR Nasdaq
- Market Cap
- IONS 4.6B
- NJR 4.6B
- IPO Year
- IONS 1991
- NJR N/A
- Fundamental
- Price
- IONS $28.40
- NJR $49.74
- Analyst Decision
- IONS Buy
- NJR Hold
- Analyst Count
- IONS 18
- NJR 5
- Target Price
- IONS $57.00
- NJR $51.60
- AVG Volume (30 Days)
- IONS 2.0M
- NJR 774.8K
- Earning Date
- IONS 04-30-2025
- NJR 05-05-2025
- Dividend Yield
- IONS N/A
- NJR 3.60%
- EPS Growth
- IONS N/A
- NJR 36.54
- EPS
- IONS N/A
- NJR 3.33
- Revenue
- IONS $705,138,000.00
- NJR $1,817,690,000.00
- Revenue This Year
- IONS N/A
- NJR $4.31
- Revenue Next Year
- IONS $25.80
- NJR $3.63
- P/E Ratio
- IONS N/A
- NJR $14.95
- Revenue Growth
- IONS N/A
- NJR 6.51
- 52 Week Low
- IONS $23.95
- NJR $41.30
- 52 Week High
- IONS $52.34
- NJR $51.95
- Technical
- Relative Strength Index (RSI)
- IONS 44.54
- NJR 61.01
- Support Level
- IONS $27.57
- NJR $45.51
- Resistance Level
- IONS $29.04
- NJR $48.49
- Average True Range (ATR)
- IONS 1.79
- NJR 1.44
- MACD
- IONS 0.12
- NJR 0.12
- Stochastic Oscillator
- IONS 68.15
- NJR 85.80
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About NJR NewJersey Resources Corporation
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include solar investments primarily in New Jersey and investments in several large midstream natural gas projects.